🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Predictive Model for Recurrence of Colorectal Cancer Based on Multi-omics of Portal Vein Blood

Recruitingn/aAges 18 Years - anyAllPeking University Shougang Hospital
NCT06524245 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This multi-center study aims to develop a precise predictive model for colorectal cancer (CRC) recurrence and metastasis based on multi-omics analysis of portal vein blood. Despite advances in surgical treatments, approximately 40% of CRC patients experience tumor recurrence or metastasis post-surgery, with 80-90% of metastases being unresectable. The study will include stage I-IV CRC patients and will be conducted in two phases: a nested case-control study and a bidirectional cohort study. Comprehensive multi-omics sequencing will be performed on samples from primary tumors, adjacent tissues, normal intestinal tissues, portal vein blood, and peripheral blood. The goal is to identify specific biomarkers in the portal vein and peripheral blood associated with CRC recurrence and metastasis, and to compare the predictive accuracy of models based on these biomarkers. The ultimate objective i

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18 years or older * Histologically confirmed stage I-IV colorectal cancer (CRC) * Availability of pre-operative and intra-operative blood samples (portal vein and peripheral blood) and primary tumor tissue samples * No neoadjuvant therapy before surgery Exclusion Criteria: * Prior history of other malignancies * Incomplete clinical information or pathology reports * Incomplete follow-up records
💊

What it tests

  • Not listed
📍

Where

1 site
Peking University Shougang Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy